Members of our Corporate and Finance teams advised EQT on the Initial Public Offering of their Private Equity portfolio company, Galderma.

Galderma priced its initial IPO on SIX Swiss Exchange at CHF 53 per share and closed at CHF 64 per share at the end of the first trading day, implying a market capitalisation of CHF 15 billion (USD 17 billion).

Our team advised EQT on the Luxembourg corporate and financial aspects.

After being acquired by EQT Private Equity and a consortium of co-investors, Galderma has evolved from being a non-core subsidiary of Nestlé to becoming a prominent leader in the dermatology sector, focusing solely on this category.

Galderma has leading positions across three of the most attractive market segments – Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology – and a presence in more than 90 countries with one of the broadest portfolios of clinically proven flagship brands in dermatology.

EQT is a purpose-driven global investment organisation focused on active ownership strategies.